{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:58:38Z","timestamp":1789167518763,"version":"build-2803163510"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:00:00Z","timestamp":1760832000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004434","name":"University of Florence","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007366","name":"Fondazione Italiana Sclerosi Multipla","doi-asserted-by":"publisher","award":["2024\/R-Single\/038"],"award-info":[{"award-number":["2024\/R-Single\/038"]}],"id":[{"id":"10.13039\/100007366","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031478","name":"NextGenerationEU","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.neuropharm.2025.110724","type":"journal-article","created":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:01:31Z","timestamp":1760911291000},"page":"110724","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Adenosine A2A receptor blockade promotes oligodendrocyte differentiation and myelination: Highlighting the potency of an edaravone-conjugated A2A receptor antagonist"],"prefix":"10.1016","volume":"282","author":[{"given":"F.","family":"Cherchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Frulloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Venturini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Magni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Calenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Innocenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Varano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Catarzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ceni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Vagnoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Colotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Vincenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Varani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Prisinzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Donati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Cencetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Coppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Pugliese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2025.110724_bib1","doi-asserted-by":"crossref","first-page":"5878","DOI":"10.1007\/s12035-023-03440-6","article-title":"Roles of adenosine receptor (subtypes A1 and A2A) in cuprizone-induced hippocampal demyelination","volume":"60","author":"Adebiyi","year":"2023","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2025.110724_bib2","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.2174\/0929867326666190124122752","article-title":"Oxidative status in multiple sclerosis and off-targets of antioxidants: the case of edaravone","volume":"27","author":"Agresti","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.neuropharm.2025.110724_bib3","doi-asserted-by":"crossref","DOI":"10.1007\/s11033-025-10343-3","article-title":"Edaravone reduces brain injury in hepatic encephalopathy by upregulation of Nrf2\/HO-1 and inhibition of NF-\u03baB, iNOS\/NO and inflammatory cytokines","volume":"52","author":"Amirshahrokhi","year":"2025","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.neuropharm.2025.110724_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/nrc3613","article-title":"Immunity, inflammation and cancer: a leading role for adenosine","author":"Antonioli","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.neuropharm.2025.110724_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119812","article-title":"Evaluation of edaravone effects on the differentiation of human adipose derived stem cells into oligodendrocyte cells in multiple sclerosis disease in rats","volume":"282","author":"Bakhtiari","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2025.110724_bib6","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/NEN.0b013e3181aba2c1","article-title":"Peroxisome proliferator-activated receptor-\u03b3 agonists promote differentiation and antioxidant defenses of oligodendrocyte progenitor cells","volume":"68","author":"Bernardo","year":"2009","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2025.110724_bib48","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1365-2818.2006.01706.x","article-title":"A guided tour into subcellular colocalization analysis in light microscopy","volume":"224","author":"Bolte","year":"2006","journal-title":"J. Microsc."},{"key":"10.1016\/j.neuropharm.2025.110724_bib50","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1073\/pnas.052704499","article-title":"Thyroid hormone activates oligodendrocyte precursors and increases a myelin-forming protein and NGF content in the spinal cord during experimental allergic encephalomyelitis","volume":"99","author":"Calza","year":"2002","journal-title":"Proc. Nat. Acad. Sci. United States of America"},{"key":"10.1016\/j.neuropharm.2025.110724_bib44","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.neuron.2004.06.024","article-title":"NGF controls axonal receptivity to myelination by Schwann cells or oligodendrocytes","volume":"43","author":"Chan","year":"2004","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2025.110724_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2019.104490","article-title":"The adenosine A2A receptor antagonist SCH58261 reduces macrophage\/microglia activation and protects against experimental autoimmune encephalomyelitis in mice","volume":"129","author":"Chen","year":"2019","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2025.110724_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22147277","article-title":"Ion channels as new attractive targets to improve re\u2010myelination processes in the brain","author":"Cherchi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2025.110724_bib9","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.4103\/1673-5374.306058","article-title":"Oligodendrocyte precursor cell maturation: role of adenosine receptors","volume":"16","author":"Cherchi","year":"2021","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.neuropharm.2025.110724_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/glia.24593","article-title":"Adenosine A2B receptors differently modulate oligodendrogliogenesis and myelination depending on their cellular localization","volume":"72","author":"Cherchi","year":"2024","journal-title":"Glia"},{"key":"10.1016\/j.neuropharm.2025.110724_bib11","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.neuropharm.2013.05.035","article-title":"Adenosine A2A receptors inhibit delayed rectifier potassium currents and cell differentiation in primary purified oligodendrocyte cultures","volume":"73","author":"Coppi","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2025.110724_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113956","article-title":"Adenosine A2B receptors inhibit K+ currents and cell differentiation in cultured oligodendrocyte precursor cells and modulate sphingosine-1-phosphate signaling pathway","volume":"177","author":"Coppi","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110724_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/srep45780","article-title":"A staged screening of registered drugs highlights remyelinating drug candidates for clinical trials","volume":"7","author":"Eleuteri","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2025.110724_bib14","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.neuint.2003.11.015","article-title":"Volume transmission in activity-dependent regulation of myelinating glia","volume":"45","author":"Fields","year":"2004","journal-title":"Neurochem. Int."},{"issue":"9 20","key":"10.1016\/j.neuropharm.2025.110724_bib15","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41573-021-00233-1","article-title":"Targeting oxidative stress in disease: promise and limitations of antioxidant therapy","volume":"20","author":"Forman","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2025.110724_bib16","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1523\/JNEUROSCI.16-08-02659.1996","article-title":"Oligodendrocyte progenitor cell proliferation and lineage progression are regulated by glutamate receptor-mediated K+ channel block","volume":"16","author":"Gallo","year":"1996","journal-title":"J. Neurosci."},{"issue":"19","key":"10.1016\/j.neuropharm.2025.110724_bib46","doi-asserted-by":"crossref","first-page":"8055","DOI":"10.1021\/acs.jmedchem.7b00780","article-title":"Design and structure-guided development of novel inhibitors of the xeroderma pigmentosum group A (XPA) protein-DNA interaction","volume":"60","author":"Gavande","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2025.110724_bib43","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/jnc.15223","article-title":"Ethanol neurotoxicity is mediated by changes in expression, surface localization and functional properties of glutamate AMPA receptors","volume":"157","author":"Gerace","year":"2021","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2025.110724_bib52","first-page":"164","article-title":"The ameliorative effects of a phenolic derivative of Moringa oleifera leave against vanadium-induced neurotoxicity in mice","volume":"9","author":"Igado","year":"2020","journal-title":"IBRO Neurosci. Rep."},{"key":"10.1016\/j.neuropharm.2025.110724_bib17","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12974-016-0512-z","article-title":"Dual roles of the adenosine A2a receptor in autoimmune neuroinflammation","volume":"13","author":"Ingwersen","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2025.110724_bib18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejphar.2016.08.003","article-title":"Edaravone alleviates cisplatin-induced neurobehavioral deficits via modulation of oxidative stress and inflammatory mediators in the rat hippocampus","volume":"791","author":"Jangra","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110724_bib53","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1523\/JNEUROSCI.4175-06.2007","article-title":"NGF regulates the expression of axonal LINGO-1 to inhibit oligodendrocyte differentiation and myelination","volume":"27","author":"Lee","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110724_bib19","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212\u0394\u0394CT method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.neuropharm.2025.110724_bib20","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/glia.24271","article-title":"Remyelination in neuromyelitis optica spectrum disorder is promoted by edaravone through mTORC1 signaling activation","volume":"71","author":"Luo","year":"2023","journal-title":"Glia"},{"key":"10.1016\/j.neuropharm.2025.110724_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177686","article-title":"Edaravone protects against cuprizone-induced demyelination in rats by modulating TNF-\u03b1\/NF-\u0138B\/NLRP3 signaling and the kynurenine pathway","volume":"999","author":"Mahmoud","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110724_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2021.748849","article-title":"Novel in vitro experimental approaches to study myelination and remyelination in the central nervous system","volume":"15","author":"Marangon","year":"2021","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110724_bib23","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.2174\/09298673113209990156","article-title":"Advances in antioxidative therapy of multiple sclerosis","volume":"20","author":"Miller","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.neuropharm.2025.110724_bib24","doi-asserted-by":"crossref","DOI":"10.1186\/1742-2094-9-193","article-title":"Extracellular adenosine signaling induces CX3CL1 expression in the brain to promote experimental autoimmune encephalomyelitis","volume":"9","author":"Mills","year":"2012","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2025.110724_bib25","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1161\/STROKEAHA.113.002813","article-title":"Oxidative stress interferes with white matter renewal after prolonged cerebral hypoperfusion in mice","volume":"44","author":"Miyamoto","year":"2013","journal-title":"Stroke; a journal of cerebral circulation"},{"key":"10.1016\/j.neuropharm.2025.110724_bib26","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1159\/000069318","article-title":"Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction: randomized, placebo-controlled, double-blind study at multicenters","volume":"15","author":"Otomo","year":"2003","journal-title":"Cerebrovasc. Dis."},{"key":"10.1016\/j.neuropharm.2025.110724_bib27","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/jcbfm.2013.85","article-title":"Adenosine A2A receptors in secondary progressive multiple sclerosis: a [ 11 C]TMSX brain PET study","volume":"33","author":"Rissanen","year":"2013","journal-title":"J. Cerebr. Blood Flow Metabol."},{"key":"10.1016\/j.neuropharm.2025.110724_bib49","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH image to ImageJ: 25\u2009years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.neuropharm.2025.110724_bib28","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1242\/jcs.03242","article-title":"Neuron-glia communication in the control of oligodendrocyte function and myelin biogenesis","volume":"119","author":"Simons","year":"2006","journal-title":"J. Cell Sci."},{"issue":"10 78","key":"10.1016\/j.neuropharm.2025.110724_bib29","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1007\/s00018-021-03802-0","article-title":"Oxidative stress and impaired oligodendrocyte precursor cell differentiation in neurological disorders","volume":"78","author":"Spaas","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.neuropharm.2025.110724_bib30","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0896-6273(02)01067-X","article-title":"Adenosine: a neuron-glial transmitter promoting myelination in the CNS in response to action potentials","volume":"36","author":"Stevens","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2025.110724_bib31","doi-asserted-by":"crossref","DOI":"10.1089\/ars.2023.0455","article-title":"Adenosine A2A receptor antagonist Sch58261 improves the cognitive function in alzheimer's disease model mice through activation of Nrf2 via an autophagy-dependent pathway","author":"Sun","year":"2024","journal-title":"Antioxidants Redox Signal."},{"key":"10.1016\/j.neuropharm.2025.110724_bib32","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.neulet.2018.01.018","article-title":"Protective effects of a radical scavenger edaravone on oligodendrocyte precursor cells against oxidative stress","volume":"668","author":"Takase","year":"2018","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2025.110724_bib33","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.4103\/1673-5374.237116","article-title":"A radical scavenger edaravone and oligodendrocyte protection\/regeneration","volume":"13","author":"Takase","year":"2018","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.neuropharm.2025.110724_bib34","doi-asserted-by":"crossref","first-page":"40104","DOI":"10.1074\/jbc.M110.184606","article-title":"Inactivation of adenosine A2A receptor attenuates basal and angiotensin II-induced ROS production by Nox2 in endothelial cells","volume":"285","author":"Thakur","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2025.110724_bib35","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.neuroscience.2009.04.065","article-title":"Edaravone attenuates white matter lesions through endothelial protection in a rat chronic hypoperfusion model","volume":"162","author":"Ueno","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2025.110724_bib51","series-title":"FDA approves oral form of edaravone for treatment of ALS","year":"2022"},{"key":"10.1016\/j.neuropharm.2025.110724_bib36","doi-asserted-by":"crossref","first-page":"10564","DOI":"10.1021\/acs.jmedchem.6b01068","article-title":"Design, synthesis, and pharmacological characterization of 2-(2-Furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine derivatives: new highly potent A2A adenosine receptor inverse agonists with antinociceptive activity","volume":"59","author":"Varano","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2025.110724_bib47","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/glia.23939","article-title":"The impact of trophic and immunomodulatory factors on oligodendrocyte maturation: Potential treatments for encephalopathy of prematurity","volume":"69","author":"Vaes","year":"2021","journal-title":"Glia"},{"key":"10.1016\/j.neuropharm.2025.110724_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ph13080161","article-title":"Piperazine-and piperidine-containing thiazolo[5,4-d]pyrimidine derivatives as new potent and selective adenosine a2a receptor inverse agonists","volume":"13","author":"Varano","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.neuropharm.2025.110724_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127067","article-title":"Structural investigation on thiazolo[5,4-d]pyrimidines to obtain dual-acting blockers of CD73 and adenosine A2A receptor as potential antitumor agents","volume":"30","author":"Varano","year":"2020","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.neuropharm.2025.110724_bib39","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3164\/jcbn.17-62","article-title":"How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis?","volume":"62","author":"Watanabe","year":"2018","journal-title":"J. Clin. Biochem. Nutr."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110724_bib40","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1111\/j.1471-4159.2010.06664.x","article-title":"Calpain-mediated down-regulation of myelin-associated glycoprotein in lysophosphatidic acid-induced neuropathic pain","volume":"113","author":"Xie","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2025.110724_bib41","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1471-4159.2012.07807.x","article-title":"Genetic inactivation of the adenosine A 2A receptor exacerbates brain damage in mice with experimental autoimmune encephalomyelitis","volume":"123","author":"Yao","year":"2012","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110724_bib42","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0165-5728(84)90041-9","article-title":"Myelin-associated glycoprotein is produced before myelin basic protein in cultured oligodendrocytes","volume":"6","author":"Zurbriggen","year":"1984","journal-title":"J. Neuroimmunol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825004320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825004320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:28:22Z","timestamp":1780633702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390825004320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":52,"alternative-id":["S0028390825004320"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110724","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adenosine A2A receptor blockade promotes oligodendrocyte differentiation and myelination: Highlighting the potency of an edaravone-conjugated A2A receptor antagonist","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110724","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"110724"}}